XML 84 R76.htm IDEA: XBRL DOCUMENT
v3.25.3

Commitments and Contingencies - Additional Information (Details) |  |  |  | 9 Months Ended |
--- | --- | --- | --- | --- | ---
Oct. 28, 2024 | Sep. 08, 2020 Debtinstrument | Jan. 21, 2020 Debtinstrument | Sep. 30, 2025 USD ($) UsdRln | Nov. 18, 2015 USD ($)
Royalty-Linked Notes |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |
Debt instrument outstanding portion | UsdRln |  |  |  | 0.04 |
Debt instrument maturity date |  |  |  | Dec. 31, 2045 |
Debt instrument price per unit |  |  |  | $ 160.00 |
Debt instrument, aggregate potential payment capped rate |  |  |  | 4,000 |
Royalty-Linked Notes | Private Placement |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |
Number of debt instruments issued | Debtinstrument |  |  | 2,579,400 |  |
Royalty-Linked Notes | 2020 Rights Offering |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |
Number of debt instruments issued | Debtinstrument |  | 11,000 |  |  |
Pfizer License Agreement |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |
Regulatory milestone payments upon approval of product |  |  |  |  | $ 20,000,000
Regulatory and sales milestone deferred payment period | 2 years |  |  |  |
Pfizer License Agreement | Minimum |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |
Regulatory and sales milestone payments upon achievement of net sales |  |  |  |  | 250,000,000
Pfizer License Agreement | Maximum |  |  |  |  |
Other Commitments [Line Items] |  |  |  |  |
Regulatory and sales milestone payments upon achievement of net sales |  |  |  |  | $ 1,000,000,000

X
- Definition Debt instrument aggregate potential payment capped rate. + References No definition available. + Details
Name: | itrm_DebtInstrumentAggregatePotentialPaymentCappedRate
Namespace Prefix: | itrm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Debt instrument outstanding portions. + References No definition available. + Details
Name: | itrm_DebtInstrumentOutstandingPortions
Namespace Prefix: | itrm_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Debt instrument price per unit. + References No definition available. + Details
Name: | itrm_DebtInstrumentPricePerUnit
Namespace Prefix: | itrm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of debt instruments issued. + References No definition available. + Details
Name: | itrm_NumberOfDebtInstrumentsIssued
Namespace Prefix: | itrm_
Data Type: | xbrli:decimalItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory and sales milestone deferred payment period. + References No definition available. + Details
Name: | itrm_RegulatoryAndSalesMilestoneDeferredPaymentPeriod
Namespace Prefix: | itrm_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory and sales milestone payments upon achievement of net sales. + References No definition available. + Details
Name: | itrm_RegulatoryAndSalesMilestonePaymentsUponAchievementOfNetSales
Namespace Prefix: | itrm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Regulatory milestone payments upon approval of product. + References No definition available. + Details
Name: | itrm_RegulatoryMilestonePaymentsUponApprovalOfProduct
Namespace Prefix: | itrm_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B + Details
Name: | us-gaap_DebtInstrumentMaturityDate
Namespace Prefix: | us-gaap_
Data Type: | xbrli:dateItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_OtherCommitmentsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_DebtInstrumentAxis=itrm_RoyaltyLinkedNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=itrm_TwoThousandAndTwentyRightsOfferingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=itrm_PfizerLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |